CDXS vs. PYXS, NYXH, SENS, JYNT, UTMD, ME, CDXC, CHRS, ZURA, and AKBA
Should you be buying Codexis stock or one of its competitors? The main competitors of Codexis include Pyxis Oncology (PYXS), Nyxoah (NYXH), Senseonics (SENS), Joint (JYNT), Utah Medical Products (UTMD), 23andMe (ME), ChromaDex (CDXC), Coherus BioSciences (CHRS), Zura Bio (ZURA), and Akebia Therapeutics (AKBA). These companies are all part of the "medical" sector.
Codexis (NASDAQ:CDXS) and Pyxis Oncology (NASDAQ:PYXS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation, community ranking and profitability.
In the previous week, Pyxis Oncology had 2 more articles in the media than Codexis. MarketBeat recorded 5 mentions for Pyxis Oncology and 3 mentions for Codexis. Codexis' average media sentiment score of 0.47 beat Pyxis Oncology's score of 0.43 indicating that Codexis is being referred to more favorably in the media.
Codexis has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Pyxis Oncology has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.
Codexis received 324 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 80.00% of users gave Pyxis Oncology an outperform vote while only 61.21% of users gave Codexis an outperform vote.
Pyxis Oncology has a net margin of 0.00% compared to Codexis' net margin of -87.73%. Pyxis Oncology's return on equity of -38.99% beat Codexis' return on equity.
Codexis presently has a consensus price target of $6.80, suggesting a potential upside of 113.17%. Pyxis Oncology has a consensus price target of $8.80, suggesting a potential upside of 132.19%. Given Pyxis Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Pyxis Oncology is more favorable than Codexis.
Pyxis Oncology has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.
78.5% of Codexis shares are owned by institutional investors. Comparatively, 39.1% of Pyxis Oncology shares are owned by institutional investors. 2.1% of Codexis shares are owned by insiders. Comparatively, 9.3% of Pyxis Oncology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Pyxis Oncology beats Codexis on 10 of the 17 factors compared between the two stocks.
Get Codexis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
